Comparative Analysis of Radiosensitizers for K-RAS Mutant Rectal Cancers

Approximately 40% of rectal cancers harbor activating K-RAS mutations, and these mutations are associated with poor clinical response to chemoradiotherapy. We aimed to identify small molecule inhibitors (SMIs) that synergize with ionizing radiation (IR) (“radiosensitizers”) that could be incorporate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleiman, Laura B., Krebs, Angela M., Kim, Stephen Y., Hong, Theodore S., Haigis, Kevin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861465/
https://www.ncbi.nlm.nih.gov/pubmed/24349411
http://dx.doi.org/10.1371/journal.pone.0082982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3861465/
https://www.ncbi.nlm.nih.gov/pubmed/24349411
http://dx.doi.org/10.1371/journal.pone.0082982

Ejemplares similares